We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
eGene announced that it has been issued U.S. Patent No. 6,870,167 "Multi-Color
Multiplexed Analysis In a Bio-Separation System," by the U.S. Patent and
Trademark Office.
Longport, a medical technology specialist in high resolution ultrasound imaging,
announced they have been informed of $1.7 million NIH grant application for
a three-year collaborative study of pressure ulcer development using the Longport
EPISCAN I-200.
Sigma Global, a direct-to-consumer marketer of pharmaceuticals and medical devices,
announced it has acquired Global Health Services, a product development company
currently focused on its SureOne diabetic insulin syringe product line, according
to Chairman and CEO Bryan Chance.
Tessera, a Seattle-based biomedical company, has released its first product,
ProstaMark EPCA (Early Prostate Cancer Antigen), as an analyte specific reagent
for commercial use in pathology laboratories to assist pathologists in their
efforts to determine if cancer is present in the prostate.
Serologicals announced that Upstate Group, its wholly owned subsidiary, obtained
the rights from the University of California to sell the anti-ZAP-70 monoclonal
antibody for diagnostic use.
Clarient and Applied Imaging
announced that the two companies have reached a settlement ending the companies'
patent infringement, unfair competition and misappropriation of trade secrets
litigation.
CryoCath Technologies has received clearance from the FDA to initiate an investigational
device exemption (IDE) study for the treatment of atrial fibrillation (AF).
Power3 Medical Products has entered into a collaborative research agreement
with New Horizons Diagnostics for the development of antibody-based diagnostic
tests for neurodegenerative disease using the company's identified protein biomarkers.